OVERVIEW
A due diligence assessment is an independent review of a company, technology, or vendor before an investment, partnership, acquisition, or purchase. In industry, it is regarded as the risk-reduction step in a deal: the reviewer tests whether the claims in a pitch hold up and reports the key risks to the decision-maker, such as an investment committee. For AI-enabled life science companies, it typically covers the technical, scientific, and clinical substance behind the claims, and it complements legal and financial diligence rather than replacing it.
serviceS
Testing whether an AI platform does what the pitch says and how defensible its architecture is
Reviewing the strength of the science, clinical strategy, and data package
Evaluating an AI vendor before a pharma or biotech buyer purchases or deploys it
Giving an investment committee a clear go, conditional, or no-go view with key risks
Delivering a rapid screen, standard review, or deep dive depending on the stage of the deal
Running a sell-side review so a startup can find gaps before investors do
Due Diligence Services |
Due Diligence Services |
■ Due Diligence Services
Luminai Group provides independent technical, scientific, and AI diligence for venture and biotech investors, angel groups and family offices, corporate venture and business development teams, and pharma and biotech buyers evaluating AI vendors.
Our reviews examine whether the technology performs as claimed, how defensible it is, and how strong the underlying science, clinical strategy, and data are.
We offer standard formats, from a rapid screen to a standard review to a deeper dive, each ending in a decision-ready memo with a clear view and the key risks.
Legal, financial, and intellectual property diligence remains with your attorneys and accountants, and we coordinate with them as needed.
